Fintel reports that on October 15, 2025, Baird upgraded their outlook for Vor Biopharma (NasdaqGS:VOR) from Neutral to ...

Shares of Vor Bio (Nasdaq: NASDAQ:VOR) rose after it reported that its partner, RemeGen (OTCPK:REGMF), met the main goal in a ...

Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that clinical data from Stage A of a Phase 3 study in China sponsored ...

The latest price target for Vor Biopharma (NASDAQ:VOR) was reported by Baird on October 15, 2025. The analyst firm set a price target for $64.00 expecting VOR to rise to within 12 months (a possible ...

Investing.com -- Vor Biopharma Inc (NASDAQ:VOR) 股价在周二盘前交易中上涨3.8%，此前其合作伙伴荣昌生物 (RemeGen)报告了telitacicept在原发性干燥综合征三期研究中的48周积极结果。

Investing.com - 贝尔德 (Baird)周二将 Vor Biopharma, Inc. (NASDAQ:VOR) 的评级从"中性"上调至"优于大市"，同时大幅提高其目标价，从20.00美元上调至64.00美元。根据 InvestingPro 数据，该股票在过去六个月内已上涨超过120%，目前基于全面的公允价值分析显示其被低估。

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Investing.com -- Vor Biopharma Inc (NASDAQ:VOR) stock gained 3.8% in premarket trading Tuesday after its collaborator RemeGen reported positive 48-week results from a Phase 3 study of telitacicept in ...

The challenges facing biotechs amid the ongoing financial fallout have resulted in the winding down of one US biotech, Vor Bio, and job losses at a clutch of other firms. Cambridge, ...